• Biodesix secures Oncimmune

    August 6, 2019 BOULDER, Colo. Biodesix, Inc. has announced its intent to extend the company’s blood-based lung cancer diagnostic portfolio with acquisition of Oncimmune Holdings Group’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States. The United Kingdom-based company’s U.S. operations, including a CLIA lab in De Soto, Kansas, will transition to Biodesix on November ... Read more
  • Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition

    August 6, 2019 Biodesix, Boulder, Colo- based company is extending its blood-based lung cancer diagnostic portfolio with the acquisition of Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S. Click to read more. About Biodesix: Biodesix is a lung cancer diagnostic company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The ... Read more
  • Immodulon adopts AI tool to accelerate pancreatic cancer clinical trial

    August 6, 2019 Immodulon to utilize biomarkers identified by Biodesix’ machine learning platform, aiming to accelerate the clinical development of its pancreatic treatment. Click to read more. About Biodesix: Biodesix is a lung cancer diagnostic company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions ... Read more
  • Biodesix, Immodulon team up for pancreatic cancer treatment

    August 6, 2019 Biodesix, Boulder, Colo, and Immodulon have announced a joint venture into biomarker research. The partnership will focus on the analysis of the circulating proteome of advanced pancreatic cancer patients treated with IMM-101 using the Biodesix Diagnostic Cortex machine learning platform. The Biodesix proprietary machine learning platform “builds on recent advances in the artificial intelligence field to ... Read more
  • Multivariate Blood Test Can Predict Outcomes for Non-Small Cell Lung Cancer

    April 9, 2019 Biodesix, Boulder, Colo, has recently presented new data demonstrating that the company’s VeriStrat test is predictive of outcomes for patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors in the frontline setting, even when adjusted for PD-L1 status.1,2   The VeriStrat test is a multivariate, mass-spectrometry based test that measures circulating proteins in the ... Read more
  • Medical Device and Diagnostic Industry

    March 14, 2019 A New Collaboration Could Be Key in the Early Detection of Lung Cancer by Omar Ford Read more
  • Clinical Omics

    March 14, 2019 Biodesix, MRM Proteomics Partner on Blood-Based Lung Cancer Diagnostics by Alex Philippidis Read more
  • Fierce Biotech

    March 14, 2019 Biodesix Partners with MRM for mass spec proteomics development by Conon Hale Read more
  • Clinical Lab Products: Test Predicts Primary Resistance to Anti-PD-1 Immunotherapy against Non-Small Cell Lung Cancer

    December 12, 2018 Biodesix’s primary immunotherapy resistance test demonstrated utility in classifying NSCLC patients treated with nivolumab by overall survival. The test classification is independent of PD-L1 status.   “Anti-PD-1 therapy is capable of restoring immunity and has greatly increased overall survival rates for patients. However, we know that this therapy does not benefit ... Read more
  • DDNews: VeriStrat proves its prognostic capabilities

    November 13, 2018     “Biodesix announced in the third quarter of 2018 that in a study of samples from non-small cell lung cancer patients, the company’s VeriStrat test was found to be a significant predictor of outcomes (independent of ECOG Performance Status categories), patient EGFR mutation status, treatment received and other clinical variables.”   Read the full story.    Read more